Tema Oncology ETF Rating $30.62 +0.42 (+1.37%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.76Holdings in CANC have an aggregate rating of Moderate Buy based on 389 analyst ratings issued in the past year covering 23 companies (71.5% of the portfolio).CANC Aggregate Price Target$30.62High Prediction$30.62Average Prediction$30.62Low Prediction$30.62Holdings in CANC have an aggregate price target of $30.62 and a range of $30.62 to $30.62 covering 23 companies (71.5% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy17 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.32%RVMDRevolution Medicines$51.35+3.6%4.1406 of 5 stars2.93$76.14 48.3%15Analyst ForecastInsider Trade5.49%LLYEli Lilly and Company$831.03+0.5%4.9964 of 5 stars2.68$948.06 14.1%25Trending NewsAnalyst UpgradeAnalyst Revision5.24%GMABGenmab A/S$33.60+2.7%4.1169 of 5 stars2.82$40.80 21.4%11Trending NewsAnalyst ForecastAnalyst Revision4.59%RHHBYRoche$44.77+0.7%2.6987 of 5 stars3.40$50.00 11.7%54.49%BBIOBridgeBio Pharma$56.22-0.7%4.2233 of 5 stars2.89$63.94 13.7%18Analyst Revision3.81%ACLXArcellx$92.99+0.7%1.8432 of 5 stars2.87$113.23 21.8%15Analyst Revision3.80%MRUSMerus$94.85-0.1%0.8807 of 5 stars2.16$93.12 -1.8%193.35%NUVLNuvalent$91.42+2.0%2.952 of 5 stars2.92$120.00 31.3%13News CoverageAnalyst ForecastInsider Trade2.85%EXELExelixis$39.13-2.2%4.7637 of 5 stars2.63$44.42 13.5%24Analyst Revision2.81%ONCBeOne Medicines$323.50+2.3%1.8924 of 5 stars2.90$340.30 5.2%102.72%IMNMImmunome$16.45+0.6%1.6022 of 5 stars2.82$23.20 41.0%112.60%ABBVAbbVie$226.79+0.2%4.6426 of 5 stars2.71$231.90 2.3%28Trending NewsAnalyst ForecastOptions VolumeAnalyst Revision2.60%BMYBristol Myers Squibb$43.48-0.3%4.9861 of 5 stars2.33$57.14 31.4%21Trending NewsAnalyst ForecastAnalyst Revision2.48%ZLABZai Lab$29.27-0.4%2.7826 of 5 stars2.63$56.35 92.6%8News CoveragePositive News2.43%IDYAIDEAYA Biosciences$28.73+1.2%4.1223 of 5 stars2.72$43.36 50.9%182.42%GILDGilead Sciences$120.61+2.0%4.8819 of 5 stars2.86$118.08 -2.1%29Positive News2.20%SNDXSyndax Pharmaceuticals$15.59+3.6%3.6525 of 5 stars2.82$38.00 143.8%11Analyst Forecast2.18%SMMTSummit Therapeutics$23.19+2.4%2.8544 of 5 stars2.50$31.29 34.9%18Analyst Upgrade2.08%LEGNLegend Biotech$33.710.0%2.8158 of 5 stars2.73$69.25 105.4%11News Coverage1.97%ARGXargenex$831.37+1.9%3.6293 of 5 stars3.00$817.53 -1.7%24Trending NewsAnalyst ForecastAnalyst Revision1.84%AMGNAmgen$301.82+1.5%4.5317 of 5 stars2.35$309.42 2.5%20Positive NewsAnalyst Revision1.69%COGTCogent Biosciences$16.68+0.7%1.7962 of 5 stars2.71$19.67 17.9%14News CoverageAnalyst Forecast1.55%MRKMerck & Co., Inc.$85.29+1.4%4.9978 of 5 stars2.29$105.00 23.1%21Trending NewsAnalyst ForecastAnalyst Revision This page (NASDAQ:CANC) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
